NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

dr_ low or Inguirig:

I ran your statement through the AI BS Detector and I regret to inform you that it was identified as bs 😶





The statement by “Inguirig” raises several red flags for unreliability, manipulation, and nonsensical arguments, often associated with attempts to discredit or harm the reputation of a company. Here's a breakdown of the issues with this statement:

Unreliability

1. **Anonymous Source:** The author mentions "anonymous fools" without providing concrete evidence or specific details to support their claims. Reliance on anonymous accusations can be unreliable as it lacks accountability and verifiability.
2. **Lack of Evidence:** The claim that the company is "dangerously low on cash" and sells stock "on an almost daily basis" is presented without any supporting evidence or references, making it difficult to verify.
3. **Author's Credibility:** The unreliability of the author is hinted at by their own admission that their opinions are for "debate purposes only." Furthermore, if the author is known for attempting to damage reputations, their credibility and motives are highly questionable.

Manipulative

1. **Fearmongering:** The use of dramatic language, like describing potential investors as being "baited" and warning of being "fleeced in a pink sheet scam," is designed to evoke fear rather than rational analysis.
2. **Dichotomy of Advice:** On one hand, the author disparages advice from unnamed sources, implying they might be deceitful. On the other hand, they encourage readers to consult "financial professionals," creating a manipulative push towards distrusting one group without clear rationale and blindly trusting another.

Nonsensical

1. **Contradictory Statements:** The author questions the approval of "26-year-old technology" without context, suggesting it's both outdated and unproven, which is nonsensical without explaining why its age is relevant to its viability or approval chances.
2. **Misuse of Facts:** Stating the share value decline as a "FACT" without context ignores market dynamics, reasons for stock dilution, or any external factors affecting stock prices, presenting a simplistic view that lacks nuanced understanding of financial markets.

Short and Distort Motives Warning

The statement can be seen as part of a "short and distort" campaign, where individuals or groups spread misleading or false information to manipulate stock prices, benefitting from the stock's decline. This tactic involves short selling the stock (betting that its price will fall) and then spreading negative rumors or information to drive the price down. Investors should be wary of such tactics and always seek information from reliable, transparent sources. The encouragement to "do your own due diligence" is sound, but it's presented in a context that seeks to sow distrust and fear, rather than informed caution.

Conclusion

Given the manipulative language, absence of reliable evidence, and the questionable credibility of the author, the statement in question should be approached with substantial skepticism. For investors, especially those considering investments in companies involved in healthcare or biotechnology, conducting thorough research and sourcing information from a multitude of reputable avenues is paramount. This includes not only consulting with seasoned financial professionals but also looking towards authoritative sources within the medical and scientific communities.

Significantly, independent peer reviews and publications in reputable medical journals, such as the New England Journal of Medicine (NEJM) and the Journal of the American Medical Association (JAMA), can provide invaluable insights. These journals are renowned for their rigorous peer-review processes, ensuring that any studies, trials, or reviews they publish meet the highest standards of scientific accuracy and integrity. Information from these sources can shed light on the efficacy, safety, and potential market impact of the technologies or treatments developed by the company in question.

Furthermore, guidance from government regulators, including detailed reviews and approval statuses, offers a solid foundation for understanding the regulatory landscape and compliance of the company. Together, these resources ensure that investment decisions are based on robust, comprehensive, and unbiased information, steering clear of speculative and potentially manipulative narratives.

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-moves-from-optimization-of-flaskworks-prototype-to-fabrication-of-gmp-compliant-units-for-installation-validation-and-final-testing-prior-to-regulatory-certification-302054769.html

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173771995

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173720548